142 related articles for article (PubMed ID: 23660957)
1. Tumor suppressor genes associated with drug resistance in ovarian cancer (review).
Yin F; Liu X; Li D; Wang Q; Zhang W; Li L
Oncol Rep; 2013 Jul; 30(1):3-10. PubMed ID: 23660957
[TBL] [Abstract][Full Text] [Related]
2. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
3. Distinct and competitive regulatory patterns of tumor suppressor genes and oncogenes in ovarian cancer.
Zhao M; Sun J; Zhao Z
PLoS One; 2012; 7(8):e44175. PubMed ID: 22952919
[TBL] [Abstract][Full Text] [Related]
4. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.
Eliopoulos AG; Kerr DJ; Herod J; Hodgkins L; Krajewski S; Reed JC; Young LS
Oncogene; 1995 Oct; 11(7):1217-28. PubMed ID: 7478541
[TBL] [Abstract][Full Text] [Related]
5. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function.
Gao L; Wu ZX; Assaraf YG; Chen ZS; Wang L
Drug Resist Updat; 2021 Jul; 57():100770. PubMed ID: 34175687
[TBL] [Abstract][Full Text] [Related]
6. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
7. [Tumor suppressors--genes and proteins].
Lothe RA; Blomhoff HK
Tidsskr Nor Laegeforen; 1998 May; 118(12):1887-92. PubMed ID: 9638059
[TBL] [Abstract][Full Text] [Related]
8. The epigenetics of ovarian cancer drug resistance and resensitization.
Balch C; Huang TH; Brown R; Nephew KP
Am J Obstet Gynecol; 2004 Nov; 191(5):1552-72. PubMed ID: 15547525
[TBL] [Abstract][Full Text] [Related]
9. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis.
Gorringe KL; Ramakrishna M; Williams LH; Sridhar A; Boyle SE; Bearfoot JL; Li J; Anglesio MS; Campbell IG
Genes Chromosomes Cancer; 2009 Oct; 48(10):931-42. PubMed ID: 19603523
[TBL] [Abstract][Full Text] [Related]
10. Oncogenes and tumor suppressor genes: comparative genomics and network perspectives.
Zhu K; Liu Q; Zhou Y; Tao C; Zhao Z; Sun J; Xu H
BMC Genomics; 2015; 16 Suppl 7(Suppl 7):S8. PubMed ID: 26099335
[TBL] [Abstract][Full Text] [Related]
11. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer.
Yin F; Liu X; Li D; Wang Q; Zhang W; Li L
Int J Oncol; 2013 Apr; 42(4):1305-16. PubMed ID: 23404140
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.
Anthoney DA; McIlwrath AJ; Gallagher WM; Edlin AR; Brown R
Cancer Res; 1996 Mar; 56(6):1374-81. PubMed ID: 8640828
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs in ovarian cancer biology and therapy resistance.
van Jaarsveld MT; Helleman J; Berns EM; Wiemer EA
Int J Biochem Cell Biol; 2010 Aug; 42(8):1282-90. PubMed ID: 20083225
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance.
Richardson A; Kaye SB
Drug Resist Updat; 2005 Oct; 8(5):311-21. PubMed ID: 16233989
[TBL] [Abstract][Full Text] [Related]
16. Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis.
Lum E; Vigliotti M; Banerjee N; Cutter N; Wrzeszczynski KO; Khan S; Kamalakaran S; Levine DA; Dimitrova N; Lucito R
Gynecol Oncol; 2013 Aug; 130(2):369-76. PubMed ID: 23684582
[TBL] [Abstract][Full Text] [Related]
17. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
18. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma.
Zhang L; Huang J; Yang N; Liang S; Barchetti A; Giannakakis A; Cadungog MG; O'Brien-Jenkins A; Massobrio M; Roby KF; Katsaros D; Gimotty P; Butzow R; Weber BL; Coukos G
Cancer Res; 2006 May; 66(9):4627-35. PubMed ID: 16651413
[TBL] [Abstract][Full Text] [Related]
19. Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling.
Koch M; Krieger ML; Stölting D; Brenner N; Beier M; Jaehde U; Wiese M; Royer HD; Bendas G
Biochem Pharmacol; 2013 Apr; 85(8):1077-90. PubMed ID: 23396090
[TBL] [Abstract][Full Text] [Related]
20. [Chemoresistance in ovarian cancer. State of the art and future prospects].
Katsaros D; Fracchioli S; Arese P; Enria R; Cassinelli P; Mingrone K; Piccinno R; Rigault de la Longrais IA; Massobrio M
Minerva Ginecol; 1999 Dec; 51(12):483-99. PubMed ID: 10767997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
